MedTrace Logo

Nemolizumab for LS

NCT07704775 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-07-15

No results posted yet for this study

Summary

Patients ≥ 18 years of age with Lichen sclerosis (LS)

Conditions

  • Lichen Sclerosus of Vulva

Interventions

BIOLOGICAL

Nemolizumab 30 mg

Participants will be treated with subcutaneous (SC) nemolizumab injections at doses determined by patient weight.

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Melissa Mauskar, MD · University of Texas Southwestern Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2027-09-01
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07704775 on ClinicalTrials.gov